
    
      Primary Effectiveness Endpoint: The proportion of patients in clinical remission after 6
      months (without being classified as treatment failure).

      Secondary Effectiveness: PPI consumption, esophageal acid exposure, reduction in QOLRAD and
      GSRS scores and healing of reflux esophagitis.
    
  